ABSTRACT. We aimed to explore the association between the onset of ankylosing spondylitis (AS) and nt587 polymorphisms of the tumor necrosis factor receptor II (TNFRII) gene in the Han population of Hunan Province, China. Correlation analysis was performed in a case-control study involving 100 AS cases and 100 healthy controls. The nt587 single nucleotide polymorphism of the TNFRII gene was examined by polymerase chain reaction-restriction fragment length polymorphism. The relationship between AS and the frequencies of genotypes and alleles in TNFRII nt587 were analyzed using the SPSS software. There were 43 cases with the TNFRII nt587 T/T genotype, 32 cases with the TNFRII nt587 T/G genotype, and 25 cases with the TNFRII nt587 G/G genotype. In the 100 healthy controls, 56 subjects had the TNFRII nt587 5191 ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 13 (3): 5190-5198 (2014) Relationship between TNFRII polymorphisms and AS T/T genotype, 34 had the TNFRII nt587 T/G genotype, and 10 had the TNFRII nt587 G/G genotype. The G allele frequency of the AS group was significantly higher (χ 2 = 8.734, P = 0.003) than that in the control group (41.0 vs 27.0%). The odds ratio (OR) in AS cases with the TNFRII nt587 G/G genotype was 3.256, which was obviously higher than in those with T/G (OR = 1.226) and T/T (OR = 1.0) genotype. The polymorphism at position nt587 of the TNFRII gene was found to be associated with AS, and the TNFRII nt587 G allele may play an important role in AS susceptibility. The TNFRII nt587 G/G genotype may increase the risk of developing AS in the Hunan population.
Arthritis (RA) group with a clinical classification category of CCC 202. They were matched with an equal number of respondents without RA as controls in order to minimize the sample selection bias, using Greedy Match Propensity Score Matching. Pre-disposing, enabling and need variables were matched using Chi-square tests for categorical variables and t-tests for continuous variables in SAS, version 9. Health-related quality of life instruments used were the Physical Component Summary (PCS-12) and the Mental Component Summary (MCS-12) of the SF-12 Health Survey and the EuroQol 5D index. T-tests in STATA (R) were used to measures group differences. RESULTS: Patients were statiscally matched on nine of ten variables. The mean (SE) PCS-12 scores for the RA and Non-RA groups were 34.25 (1.03) and 45.46 (1.07). The mean (SE) MCS-12 scores for the RA and Non-RA groups were 47.50 (1.01) and 51.14 (0.83). The mean (SE) EQ-5D index scores for the RA and Non-RA groups were 0.74 (0.02) and 0.86 (0.01). All lower scores were significant at an a priori alpha value of 0.05. CONCLUSIONS: Lower scores on all measures indicate that non-institutionalized adults with self-reported Rheumatoid Arthritis (RA) have a significantly lower health-realated quality of life.
baseline, patients in the EIG reported higher mean scores of physical component (PCS) (42.7 vs. 35.8) and mental component (MCS) (47.5 vs. 43.0), as well as physical functioning (48.4 vs. 42.6), role physical (39.0 vs. 30.9), bodily pain (45.2 vs. 38.2), general health (36.9 vs. 31.4), vitality (52.5 vs. 47.6), social functioning (37.4 vs. 33.0), role emotional (45.8 vs. 38.7) and mental health (52.8 vs. 46.9). All differences between the two groups were statistically significant at pϽ 0.05. After 14 weeks of Infliximab treatment, PCS and MCS had statistically significant improvements (10.7 and 9.8 respectively) from the baseline in the NIG, as well as all sub-domains of SF-12; in the EIG, there were significant improvements in PCS (8.1), general health (10.2) and mental health (4.1) from the baseline. CONCLUSIONS: The QOL was significantly better for patients who received Infliximab therapy than for those not treated with Infliximab. Infliximab initiating treatment and maintenance therapy both help improve patients QOL. The results indicate that Infliximab improves the quality of life of AS patients in China.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.